We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?
Read MoreHide Full Article
Key Takeaways
CAH is set to report Q1 fiscal 2027 earnings on Nov. 5, with EPS estimated at $2.92 on $66.96B in revenues.
Strong pharmaceutical demand, specialty expansion and generics performance could support CAH's growth.
CAH's medical distribution business faces fuel and commodity cost pressures despite operational improvements.
Cardinal Health (CAH - Free Report) is scheduled to report first-quarter fiscal 2027 results on Nov. 5, before the market opens. The company entered the quarter with strong pharmaceutical demand, expanding specialty operations and ongoing improvement initiatives in its medical distribution business.
However, its shares have underperformed the broader market, and it is unlikely to beat earnings estimate this season. Investors will likely closely monitor the company's first-quarter earnings call for indications of whether recent operating momentum can sustain earnings growth throughout the remainder of the fiscal year.
Cardinal Health’s shares declined 6.3% during the three months ended Sept. 30, 2026, underperforming the industry's 4.8% gain and the S&P 500's 1.5% growth.
Image Source: Zacks Investment Research
CAH has lagged the industry despite reporting solid fourth-quarter fiscal 2026 results. The underperformance raises the importance of management's commentary on pharmaceutical demand, specialty growth and execution in Global Medical Products and Distribution (“GMPD”).
Earnings Surprise History
Cardinal Health beat on earnings in each of the trailing four quarters, delivering an average surprise of 14.72%.
The last quarter's reported EPS of $2.91 surpassed the $2.42 estimate by 20.25%.
Image Source: Zacks Investment Research
Consensus Estimates and Revisions
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at $2.92 per share compared with $2.55 reported a year earlier. The consensus estimate for revenues is pinned at $66.96 billion compared with $64.01 billion in the prior-year quarter. The EPS and revenue estimates indicate a year-over-year improvement of 14.5% and 4.6%, respectively.
The EPS estimate has remained unchanged at $2.92 over the past seven days, indicating a stable near-term earnings outlook rather than a recent upward revision.
Quarterly Drivers and Challenges
Pharmaceutical and Specialty Solutions
Cardinal Health's Pharmaceutical and Specialty Solutions segment is likely to have remained the primary earnings driver during the fiscal first quarter. Strong demand across key pharmaceutical categories, continued specialty growth and favorable performance in the generics program supported fourth-quarter results. Per management, these trends should have continued into fiscal 2027.
Specialty operations should have provided additional support through higher-margin distribution and commercialization services. The company has expanded its BioPharma Solutions capabilities and secured additional gene therapy commercialization agreements. These developments may strengthen its long-term growth opportunities, although their immediate contribution to first-quarter earnings remains uncertain.
Medical Distribution Improvement
GMPD remains a key area to monitor going forward. During the fourth-quarter earnings call, management highlighted progress from simplification initiatives and operational improvements, although the business continues to face cost pressures. Management also indicated that elevated fuel and commodity costs could push GMPD toward the lower end of its fiscal 2027 profit guidance, if those pressures persist. These trends are likely to have constrained segmental performance during the soon-to-be-reported quarter. The company expects tariff-related benefits to have largely offset the adverse impact. However, realizing these anticipated benefits remains a key execution risk.
Investors are likely to focus on updates related to simplification initiatives and operational improvements during the first-quarter earnings call.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Our proven model does not conclusively predict an earnings beat for CAH this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Becton, Dickinson and Company (BDX - Free Report) and Globus Medical (GMED - Free Report) .
Glaukos, sporting a Zacks Rank #1, reported third-quarter 2026 earnings per share of 47 cents, which beat the Zacks Consensus Estimate by 491.67%. Revenues of $211 million surpassed the Zacks Consensus Estimate by 24.99%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Becton, Dickinson and Company, currently carrying a Zacks Rank #2, reported second-quarter 2026 adjusted EPS of $3.23, which beat the Zacks Consensus Estimate by 2.87%. Revenues of $4.98 billion surpassed the Zacks Consensus Estimate by 1.81%.
Becton, Dickinson and Company has an estimated long-term earnings growth rate of 1.1%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%.
Globus Medical, carrying a Zacks Rank of 2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
View the Zacks #1 Rank List
Image: Bigstock
Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?
Key Takeaways
Cardinal Health (CAH - Free Report) is scheduled to report first-quarter fiscal 2027 results on Nov. 5, before the market opens. The company entered the quarter with strong pharmaceutical demand, expanding specialty operations and ongoing improvement initiatives in its medical distribution business.
However, its shares have underperformed the broader market, and it is unlikely to beat earnings estimate this season. Investors will likely closely monitor the company's first-quarter earnings call for indications of whether recent operating momentum can sustain earnings growth throughout the remainder of the fiscal year.
Cardinal Health’s shares declined 6.3% during the three months ended Sept. 30, 2026, underperforming the industry's 4.8% gain and the S&P 500's 1.5% growth.
Image Source: Zacks Investment Research
CAH has lagged the industry despite reporting solid fourth-quarter fiscal 2026 results. The underperformance raises the importance of management's commentary on pharmaceutical demand, specialty growth and execution in Global Medical Products and Distribution (“GMPD”).
Earnings Surprise History
Cardinal Health beat on earnings in each of the trailing four quarters, delivering an average surprise of 14.72%.
The last quarter's reported EPS of $2.91 surpassed the $2.42 estimate by 20.25%.
Image Source: Zacks Investment Research
Consensus Estimates and Revisions
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at $2.92 per share compared with $2.55 reported a year earlier. The consensus estimate for revenues is pinned at $66.96 billion compared with $64.01 billion in the prior-year quarter. The EPS and revenue estimates indicate a year-over-year improvement of 14.5% and 4.6%, respectively.
The EPS estimate has remained unchanged at $2.92 over the past seven days, indicating a stable near-term earnings outlook rather than a recent upward revision.
Quarterly Drivers and Challenges
Pharmaceutical and Specialty Solutions
Cardinal Health's Pharmaceutical and Specialty Solutions segment is likely to have remained the primary earnings driver during the fiscal first quarter. Strong demand across key pharmaceutical categories, continued specialty growth and favorable performance in the generics program supported fourth-quarter results. Per management, these trends should have continued into fiscal 2027.
Specialty operations should have provided additional support through higher-margin distribution and commercialization services. The company has expanded its BioPharma Solutions capabilities and secured additional gene therapy commercialization agreements. These developments may strengthen its long-term growth opportunities, although their immediate contribution to first-quarter earnings remains uncertain.
Medical Distribution Improvement
GMPD remains a key area to monitor going forward. During the fourth-quarter earnings call, management highlighted progress from simplification initiatives and operational improvements, although the business continues to face cost pressures. Management also indicated that elevated fuel and commodity costs could push GMPD toward the lower end of its fiscal 2027 profit guidance, if those pressures persist. These trends are likely to have constrained segmental performance during the soon-to-be-reported quarter. The company expects tariff-related benefits to have largely offset the adverse impact. However, realizing these anticipated benefits remains a key execution risk.
Investors are likely to focus on updates related to simplification initiatives and operational improvements during the first-quarter earnings call.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote
What Our Model Unveils for Cardinal Health Stock
Our proven model does not conclusively predict an earnings beat for CAH this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: CAH has a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Becton, Dickinson and Company (BDX - Free Report) and Globus Medical (GMED - Free Report) .
Glaukos, sporting a Zacks Rank #1, reported third-quarter 2026 earnings per share of 47 cents, which beat the Zacks Consensus Estimate by 491.67%. Revenues of $211 million surpassed the Zacks Consensus Estimate by 24.99%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Becton, Dickinson and Company, currently carrying a Zacks Rank #2, reported second-quarter 2026 adjusted EPS of $3.23, which beat the Zacks Consensus Estimate by 2.87%. Revenues of $4.98 billion surpassed the Zacks Consensus Estimate by 1.81%.
Becton, Dickinson and Company has an estimated long-term earnings growth rate of 1.1%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%.
Globus Medical, carrying a Zacks Rank of 2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.